Teva Pharmaceutical Industries Limited (TEVA) announced that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application or ANDA to market its generic version of Takeda Pharmaceuticals North America Inc.'s Prevacid (Lansoprazole) SoluTab.
The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent . Teva said that it intends to complete an analysis of the decision before deciding upon its next course of action.
Annual sales of the brand product were about $500 million in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.